Health
Breakthroughs and beating the odds.
Experimental Drug Shows Promise in Treating Mesothelioma
An experimental drug controls disease progression in 67% of mesothelioma patients in a phase 1 trial.
Gene therapy restores immune function in 95% of ADA-SCID children
A gene therapy trial successfully restored immune function in 96% of children with ADA-SCID, a rare immune disorder.
FDA approves Kresladi gene therapy for rare immune disorder
Kresladi, a new gene therapy, gains FDA approval for treating severe leukocyte adhesion deficiency-I, improving patient outcomes.
Phase 3 trial shows promise for personalized mRNA cancer vaccine
Merck and Moderna's cancer vaccine, intismeran autogene, meets key endpoints for melanoma treatment.
India exceeds 8 million HPV vaccinations in national campaign
India has administered over 8 million doses of the HPV vaccine to girls as part of a national health initiative.
Bepirovirsen Shows Promise for Chronic Hepatitis B Cure
Bepirovirsen achieves functional cure rates of up to 26% in Phase 3 trials for chronic hepatitis B.
FDA Approves Ensitrelvir as First Oral Antiviral for COVID-19 Prevention
The FDA has approved ensitrelvir for COVID-19 post-exposure prevention in adults and adolescents.
Gene Therapy Restores Immune Function in 95% of Children with ADA-SCID
A gene therapy has restored immune function in 59 of 62 children with ADA-SCID, offering hope for a deadly genetic disorder.
Moderna's mRNA flu vaccine approved for adults 50 and older
The FDA has approved Moderna's mFLUSIVA, the first mRNA flu vaccine, for adults aged 50 and above.
Lancet Review Confirms Safety and Effectiveness of mRNA Vaccines
A Lancet review confirms mRNA vaccines are 87% effective against SARS-CoV-2 infections.
NOUS-209 vaccine shows promise in preventing Lynch syndrome cancers
Early data indicates the NOUS-209 vaccine may prevent cancers related to Lynch syndrome.
Wolbachia mosquito releases greatly reduce dengue risk in Singapore
A trial in Singapore shows Wolbachia-infected mosquitoes cut dengue rates by over 70%.
FDA Approves First mRNA Seasonal Influenza Vaccine for Seniors
Moderna's mFlusiva is the first mRNA influenza vaccine approved for adults 50 and older.
WRSs2 Shigella Vaccine Shows 89% Efficacy in Phase 2 Trial
The WRSs2 oral Shigella vaccine demonstrated 89% efficacy in a Phase 2 trial, marking a significant advancement in vaccine development.
Oxford Vaccine Group advances Bundibugyo Ebola vaccine to trials
The Oxford Vaccine Group has completed preclinical testing for a Bundibugyo Ebola vaccine and is set for phase I trials.
GSK's Bepirovirsen Shows 19% Functional Cure in Hepatitis B Trials
GSK's bepirovirsen demonstrated a 19% functional cure rate in hepatitis B phase 3 trials.
mKRAS-VAX vaccine shows promise in pancreatic cancer trial
A phase 1 trial of the mKRAS-VAX vaccine demonstrated a durable immune response in 90% of high-risk pancreatic cancer patients.
FDA Approves Xocova as First Oral Therapy for COVID-19 Prevention
Xocova becomes the first oral therapy approved by the FDA for COVID-19 post-exposure prophylaxis in adults and adolescents.
Novavax's XFG-variant COVID-19 vaccine approved in multiple regions
Novavax's XFG variant-adapted vaccine receives approvals for the 2026-2027 season in the US, EU, and Japan.
GSK and Ionis report Phase 3 success for hepatitis B treatment
GSK and Ionis announce successful Phase 3 trials for bepirovirsen, a potential treatment for chronic hepatitis B.
NOUS-209 Vaccine Shows Promise for Lynch Syndrome Cancer Prevention
Early trials of the NOUS-209 vaccine indicate it can induce T-cell responses against cancer in Lynch syndrome patients.
WHO Celebrates Disease Elimination Achievements in South-East Asia
The WHO recognized significant public health milestones in South-East Asia on September 8, 2026, including trachoma elimination.
Nanoparticle Vaccine Advances Hepatitis C Prevention Efforts
Scripps Research scientists developed a nanoparticle-based vaccine candidate for hepatitis C, showing promising results in mice.
Bepirovirsen shows 19% functional cure rate for hepatitis B
GSK reports a 19% functional cure rate for chronic hepatitis B with bepirovirsen in phase 3 trials, a significant advance in treatment.
FDA Approves Ensitrelvir for COVID-19 Post-Exposure Prevention
Ensitrelvir, the first oral antiviral for COVID-19 prevention, receives FDA approval for adults and adolescents.
WRSs2 Shigella vaccine shows 89% efficacy in phase 2 trial
The WRSs2 vaccine demonstrated 89% protection against Shigella sonnei in a phase 2 trial with 73 participants.
Shigella vaccine candidate shows 89% efficacy in trial
The WRSs2 vaccine achieved 89% efficacy in a phase 2 trial against Shigella sonnei, the highest for any candidate.
FDA Approves First Oral Therapy for Covid-19 Prevention
The FDA has approved Shionogi’s Xocova as the first oral therapy for Covid-19 post-exposure prophylaxis in adolescents and adults.
Moderna and Merck report mRNA vaccine reduces melanoma risk
A trial shows an mRNA vaccine significantly lowers melanoma recurrence risk in high-risk patients.
UCLA trial shows cancer vaccine elicits strong immune response
A novel cancer vaccine targeting KRAS mutations shows strong immune responses in patients with pancreatic and colorectal cancer.
FDA Approves Monthly Injection for Ulcerative Colitis Treatment
The FDA has approved a new once-monthly injection regimen for Eli Lilly’s Omvoh to treat ulcerative colitis.
Cambridge's pEVAC-PS Vaccine Trial Shows Positive Results
The University of Cambridge has completed a phase 1 trial of an AI-designed vaccine, pEVAC-PS, targeting sarbecoviruses.
FDA Approves First Gene Therapy for Wiskott-Aldrich Syndrome
Waskyra, the first gene therapy for Wiskott-Aldrich syndrome, shows significant reduction in severe infections and bleeding events.
UCLA KRAS Vaccine Shows Promising Results in Cancer Trial
A novel cancer vaccine, ELI-002 2P, demonstrated strong immune responses in 25 patients with KRAS-driven cancers.
WRSs2 Shigella Vaccine Shows 89% Efficacy in Phase 2 Trial
A Phase 2 trial found the WRSs2 vaccine provided 89% protection against Shigella sonnei infection.
FDA Approves Kresladi Gene Therapy for Immune Disorder
The FDA has approved Kresladi, a gene therapy for severe leukocyte adhesion deficiency-I, providing new hope for patients.
FDA approves new viral immunotherapy for advanced melanoma
The FDA has granted accelerated approval for Tudriqev, a new oncolytic viral therapy for advanced melanoma, on August 29, 2026.
CAR T-cell therapy shows promise for severe rheumatoid arthritis
CAR T-cell therapy has led to significant improvements in patients with severe rheumatoid arthritis, with some achieving remission.
AI-Designed Coronavirus Vaccine Passes First Human Trial
A novel AI-designed universal coronavirus vaccine has successfully completed its first human trial, demonstrating safety and efficacy.
Rotavirus vaccine decreases gastroenteritis deaths by 75.8%
A global study reveals the rotavirus vaccine cuts deaths from gastroenteritis by 75.8% among vaccinated children.
GSK drug bepirovirsen shows functional cure for hepatitis B in trials
GSK’s bepirovirsen achieved functional cures in 19-20% of hepatitis B patients in two Phase 3 trials.
Phase 2 Trial Shows 89% Efficacy for Shigella Vaccine
A phase 2 trial for the WRSs2 vaccine against Shigella sonnei achieved 89% efficacy with no serious adverse events.
Gene Therapy Restores Immune Function in 95% of ADA-SCID Children
A gene therapy for ADA-SCID has restored immune function in 59 of 62 treated children, achieving a 95% success rate.
Moderna and Merck's mRNA cancer vaccine shows promise in Phase 3 trial
A Phase 3 trial indicates that the mRNA vaccine intismeran autogene reduces melanoma recurrence risk.
GSK's Bepirovirsen Shows Promise as Functional Cure for Hepatitis B
GSK's bepirovirsen achieved functional cures in 19% of participants in phase 3 trials for hepatitis B.
EPA updates testing methods to reduce animal use in chemical safety reviews
The U.S. EPA announces advancements to modernize chemical safety assessments while minimizing animal testing.
Wolbachia mosquito release reduces dengue infections in Singapore
A trial in Singapore showed that releasing Wolbachia-infected mosquitoes cut dengue infections by 71-72% among residents.
FDA Approves Kresladi, First Gene Therapy for Severe LAD-I
The FDA has approved Kresladi, the first gene therapy for severe leukocyte adhesion deficiency-I, restoring immune function in children.
Stem Cell Scaffold Enhances Vision in First Human Trial for ARK
A dual stem cell scaffold improved vision in a first-in-human trial for aniridia-related keratopathy at Moorfields Eye Hospital.
Gene Therapy Restores Immune Function in Children with ADA-SCID
An experimental gene therapy has successfully restored immune function in 59 of 62 children with ADA-SCID.